Skip to main content

2019 RORgamma Antagonists and Agonists Competitor Analysis - ResearchAndMarkets.com

The "Competitor Analysis: RORgamma Antagonists and Agonists" report has been added to ResearchAndMarkets.com's offering.

This Competitive Intelligence report about RORgamma Antagonists and Agonists evaluates the landscape of investigational small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (ROR) for treatment of inflammatory diseases and cancer as of September 2019.

The transcription factor ROR plays a critical role in the expression of pro-inflammatory cytokine interleukin IL-17 and is, therefore, an attractive target for the treatment of inflammatory diseases. Interest in this molecular target has been heightened by the advancement of orally and topically administered ROR modulators into clinical trials.

Some studies found ROR to be upregulated in cancer tissues compared with normal tissues. Furthermore, synthetic ROR agonists modulate immune cell gene expression to increase effector T-cell activity and decrease immune suppression

The report includes a compilation of currently active projects in research and development of RORgamma antagonists and agonists for the treatment of inflammatory diseases and cancer, respectively. In addition, the report lists company-specific R&D pipelines of antagonists and agonists of RORgamma.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage and additional comments with a hyperlink leading to the source of information.

Key Topics Covered:

  • RORgamma Antagonists / Inverse Agonists for Inflammatory Diseases
  • RORgamma Agonists for Cancer
  • Corporate RORgamma Antagonist & Agonist R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/r/od29t7

Contacts:

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.